An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2018
At a glance
- Drugs LNP-023 (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Feb 2018 Planned number of patients changed from 60 to 48.
- 02 Feb 2018 Planned End Date changed from 2 Apr 2018 to 17 Jan 2019.
- 02 Feb 2018 Planned primary completion date changed from 2 Apr 2018 to 17 Jan 2019.